Tech Coast Angels - San Diego

Our mission is to be the BEST place for the BEST companies to raise their seed financing.

TCA-SD ChapterTCA Network


TCA-San Diego (TCA-SD) is the San Diego chapter of Tech Coast Angels – one of the largest and most active angel investment networks in the country. You can learn more about the Tech Coast Angels network here.

About TCA-SD

  • We are the largest TCA chapter with over 200 active accredited investors from all walks of life

  • TCA-SD invested over $12M in 2019. We focus mainly on Tech (software, hardware, cleantech, etc.) and Life Science (biotech, medical devices, pharma, genomics, diagnostics, digital health, etc.)

  • We are passionate about building great companies that drive economic returns for founders, investors, employees, and our community

Our Pledge to Entrepreneurs

  • We will treat you with respect
  • Time is money, literally. We will respect your time and get to YES or NO quickly – no MAYBE’s
  • Maximum 30-day due diligence process to get funding in the bank FASTER
  • We will leverage our internal and external network of service providers and co-investors to make your fundraising process as painless as possible

Have a great company that needs up to $1M in seed financing? Then click here to submit your funding application today.

Our Pledge to our Investor Members

  • We will engage with the most promising early-stage companies
  • Our active participation in the SoCal ecosystem will drive strong deal flow
  • Diverse membership, education, high-quality networking to build relationships and lasting friendships
  • TCA-SD will be a fun, inspirational…and hopefully, PROFITABLE experience

Ready to submit your membership application? Check out our membership overview here. Then click here to begin.

“TCA-SD led Fantasy Sports Co.’s seed round and my fundraising experience was excellent. The process was efficient, clear and we raised the target level of funding. After being a Quick Pitch finalist and closing FSC’s financing, the TCA members have been mentors helping with strategy, connections and press. I appreciate all they do for startups like us.”

Erik Groset
Erik GrosetCEO, Fantasy Sports Co.

“Membership in TCA has been an amazing education and investing platform. In addition to getting access to the most interesting startups, I’m able to learn by hearing diverse viewpoints from active investors. TCA’s events have also introduced me to a new community of colleagues, and friends, who are all passionate about the San Diego startup community.”

Victoria Lakers
Victoria LakersFrank M&C, Inc.
  • Recent Investments Led by TCA-SD

Tourmaline Labs


in seed financing



in seed financing

Echo Labs


in seed financing
followed by a
$7.5M Series A

Featured Portfolio Companies:

LynxBio is developing a platform technology, MicroC3, to assist doctors in rapidly identifying the most effective treatment options in cancer patients by characterizing patient-specific cancer behavior and evolution. MicroC3 creates a miniaturized living model of a patient’s cancer to assess cancer behaviors and responses to specific drugs through imaging-based analytics. LynxBio’s initial focus is on blood cancers (myeloma and leukemia) as existing technologies such as genetic testing are unavailable or inadequate. With a turnaround time of 3-5 days, LynxBio utilizes their SystemOn-Chip biopsy technology to quickly determine the most effective treatment options for an individual patient before therapy begins, and may continue to be utilized throughout the evolution of the disease to reduce the use of ineffective treatments.

Healionics is a clinical-stage company that addresses the need for improved means of vascular dialysis access for patients with kidney
failure. Their STARgraft artificial blood vessel is designed to eliminate common issues arising from other synthetic vascular grafts – occlusion of the vessel due to scar tissue and infection due to bacterial preference for conventional ePFTE material. STAR biomaterial resists infection and scarring, reducing dangerous bacterial infections and preventing degradation/impairment of the vessel and subsequent replacement. In addition to improving vascular access for hemodialysis patients, STAR biomaterial has applications in other biomedical implants and prosthetics, including coronary artery bypass and vascular access ports for needle-free dialysis.

Paradigm brings cutting-edge diagnostics and biomarker driven clinical trials to benefit cancer patients with their Paradigm Cancer Diagnostic (PCDx) genetic testing. Through Next-Gen Sequencing, and other biomarker analysis, PCDx is able to provide fast, accurate, and actionable information about the genomic and proteomic landscape of a patient’s cancer as well as recommending potential therapies based on the specific characterization of the patient’s tumor, personalizing each patient’s course of treatment. PCDx is able to provide test results in as few as 5 days, able to diagnose using lower-quality biopsy samples, and covers biomarkers associated with a wider range of therapies than competing diagnostics.

GoSite offers small businesses an all-in-one SaaS solution to manage their online presence and customer engagement, through a hub-based web interface and mobile app featuring:

• Digital placement on all major platforms (Yelp, Google/Apple Maps, Alexa) with SEO, Google management, syncing content.
• Customer messaging through text, website chat, Facebook.
• Review management, with automated review/feedback requests.
• Booking with appointment confirmations, reminders, and automatic scheduling through an embeddable template.
• Drag-and-drop website builder with automatic mobile formatting.
• CRM Contact hub with 1-click messaging, grouping, profiling.
• Payment processing – accept credit card payments on website or in person, through mobile apps and SMS, at point of sale or
during booking.

KettleSpace transforms hospitality assets (bars, restaurants, hotels) into a network of on-demand workspaces. A turnkey digital platform allows users to access the network of available spaces for meeting and working while allowing venues to upload, manage, and monetize their properties in the network. By utilizing existing infrastructure during downtime, KettleSpace is able to quickly and flexibly offer co-working and meeting spaces, in high-value hightraffic areas. Users are able to go to locations closer to their home or office rather than a central hub, venues are able to monetize offpeak hours on an as-available basis, and KettleSpace is able to quickly expand and open new locations in expensive areas without significant real estate leasing or construction costs.

Elysium Therapeutics developed a new class of abuse-deterrent opioids that protect patients from oral misuse, drug abuse, and fatal overdose, with two platform technologies that designed to enhance the ability of patients and physicians to employ effective opioidbased pain management and prescription drug abuse. One formulation stops oral abuse and overdose by making exposure to the active agent nonlinear, eliminating the ‘high’ that traditional opioids provide when abused with high doses – stopping abuse or even preventing the initial addiction. Their second technology is an opioid antagonist that can deactivate opioids in pain medicine once the prescribed usage period has passed, rendering them ineffective for trafficking.

Elemeno Health provides a cloud-based support for front-line health care teams – a context-driven micro learning platform that transforms institutional best-practices into bite-sized chunks to advance quality and patient safety at the point of care. Their ‘just-intime’ training allows medical professionals to access interactive guidelines, smart checklists, concise how-to videos, and advances adoption and adherence of best practices through recognition and gamification. Complicated practices and guidance around issues such as infection, cancer screenings, and opioid safety are brokendown and simplified into targeted training, and team members remain motivated to learn and implement them through competition with one another to improve compliance.

DTx Pharma is opening up new opportunities for RNA therapeutics by developing technology to address a critical barrier to further adoption of nucleic-acid based drugs (oligonucleotides) as a therapeutic class – delivery. Finding safe and effective ways to get RNA outside the liver would allow access to undruggable targets in autoimmune disease, neurodegenerative disease, cancer, glaucoma, or metabolic disease – as well as providing specific advantages the RNA delivery mechanism possesses with respect to duration and efficacy that differentiates it from small molecules, antibodies and other oligo mechanisms. DTx has developed lipidation technology that enables delivery of oligos in vivo at therapeutically relevant doses, allowing competition with small molecules and biologics as well as targeting areas they are unable to modulate.

Brius has developed a revolutionary orthodontic method that can be used in place of braces or aligners. Using computer vision, new materials, and a new method of moving teeth, their orthodontic appliance works invisibly due to placement behind the teeth. Traditional orthodontics move individual teeth, using surrounding teeth as anchoring; Brius moves each tooth individually and simultaneously, cutting treatment time in half and requiring only a quarter of the visits to an orthodontist that traditional braces require – with less pain and discomfort. Avoiding the aesthetic issues with braces, the strict scheduling of aligners, and even providing a more hygenic experience as they are easily cleaned and allow flossing, Brius are also able to compete at the same price point as braces or orthodontically supervised aligners.

Actuate Therapeutics develops small molecule therapeutics for the treatment of cancer and fibrotic diseases by targeting a GSK3B enzyme inhibitor. Their lead drug candidate is a first-in-class small molecule for the treatment of high impact carcinomas including glioblastoma, ovarian, breast, lung, brain, and pancreactic cancers. Results from studies have included complete and durable regressions of disease without recurrences and significant increases in overall survival, and has shown significant anti-tumor activity in models of difficult to treat cancers. Actuate is also developing compounds for the treatment of inflammation leading to fibrosis and neurodegeneration under the same principle of GSK3B regulation.

Atlazo combines an innovative and energy-efficient AI, a flexible bio-sensing interface, and low-power wireless capability in a novel System-on-Chip for the healthcare wearables and Internet of Things markets. Utilizing edge computing on a device rather than AI analysis in the cloud, Atlazo is able to offer a revolutionary proprietary signal processing capacity that will enable innovative new applications in the wearables and IOT markets that were not possible with preexisting technologies. Current devices use imagebased AI which must be uploaded to the cloud for machine learning and analysis/detection; Atlazo is able to perform AI analysis on the chip and upload only the results to the cloud – protecting your data, minimizing signal corruption or loss, and massively reducing the power needed to send information, enabling miniaturization of devices and longer battery life.

Lennd is event and venue management platform that simplifies and centralizes event operations. Event management teams can use Lennd as their core database/platform to collect, store, manage, and integrate the most critical operational information – vendors, exhibitors, sponsors, artists, inventory, documents, contracts, media, press, and volunteer credentials – Lennd will manage every relevant piece of data for an event. Working with some of the most notable event organizations around the world, including Outside Lands Music Festival, NFL, Newport Folk and Jazz Festival, Farmer’s Insurance Open, Life Is Beautiful Music and Arts Festival, and more, Lennd wants to do for events what Salesforce did for enterprise.

Grolltex – short for Graphene Rolling Technologies – creates products based in single-layer, chemical vapor deposition (CVD) generated graphene. Through advanced transfer and processing methods, Grolltex produces single-layer graphene at a cost structure better than any on the market. Their methodology enables them to reuse and optimize the copper substrate graphene is transferred from, which is ordinarily rendered unusable by the transfer process, allowing them to produce high quality, highthroughput, cost-effective, and environmentally sustainable graphene products. Grolltex is also a provider of CVD Hexagonal Boron Nitride (hBn).

Spiral Genetics develops software to compare large populations of whole human genomes at scale, working with governments, pharmaceutical companies and academic research institutions to compare and mine whole genome datasets for novel discoveries that will lead to new diagnostics and treatments. Their BioGraph Engine facilitates and accelerates the next level of genetic analysis from days to hours – combining datasets across populations to make new discoveries – by taking a fundamentally new approach to raw sequencing data and converting it to a highly efficient graph structure, eliminating trade-offs between storage footprint, computing costs, and quality of analysis. They also offer Spiral Encrypted Compression, a new method of efficient, lossless, and encrypted data archival of large genetic datasets.

Ceresti Health aims to improve the quality and reduce cost outcomes for patients with multiple chronic conditions who are also suffering from Alzheimer’s Disease and other dementias. Managing a dementia patient’s other diseases and conditions is a challenge as patients are often unable to communicate their symptoms, compounded by the fact that most caregivers are unpaid and untrained family members without nursing experience. Ceresti helps manage the difficulties presented by these patients through a digitally-aided family caregiver empowerment program, personalized to the patient and family caregiver’s needs, providing care coaching, education, and a suite of digital tools for accessing support and resources, engaging the patient, monitoring and tracking their condition, and communicating with Ceresti’s coaches.

Habitu8 is a cybersecurity provider that tackles the problem of cybersecurity at what may be the weakest point – a company’s own employees. Habitu8 is a Security Awareness Training vendor that tackles poor employee habits and ignorance of security principles through a two-pronged approach: 

Their first method is through live-action training videos (“Hashtag Awareness”) filmed with high production values and using humor to instill their messaging more effectively. 

The second method is their Learning Management Simplified platform, which allows a more engaging method of having employees meet compliance requirements, with bespoke Netflix-style videos combined with tracking and reporting features to ensure employees view all the security protocol lessons required.

iDentical utilizes 3D technology to make drill-free dental implants. After a tooth extraction, iDentical creates a 3D model of the tooth root, applies proprietary design features to it and then uses that model to manufacture the implant. Within a week of the extraction, the dentist inserts the implant in the patient’s socketsite without drilling or chance of misplacement. 

Dental implants today utilize a 50-year-old drill-and-screw technology that is highly invasive, lengthy and expensive, and it’s only offered by dental specialists and 1 in 10 dentists. The current procedure involves drilling a hole into the patient’s jawbone, which can cause nerve damage, takes 7-10 months to complete and costs up to $6,000 per tooth, making dental implants inaccessible to people who need them. 

iDentical provides the dentist with a low-risk, high-margin revenue stream that requires minimal training, no capital investment and meaningful differentiation for their dental practice.

Echo, formerly Echo Laboratories, is setting a new precedent in microscope usability and design. Their hybrid microscope, Revolve, was the world’s first Hybrid Microscope that transforms between Upright and Inverted configurations, eliminating the need for two separate instruments. Eyepieces are replaced with an iPad tablet to view and capture images with ease. Echo’s software app simplifies the workflow of acquiring, sharing, and analyzing images, delivering a modern, seamless approach to data management and hardware integration. 

Echo has had $25 million in sales since winning TCA’s QuickPitch 2016, and is preparing to launch two new microscopes, Hyperscope and Revolution, in 2020.

Heart Health Intelligence has designed and developed The Heart Seat, a unique cloud-connected toilet seat-based platform that captures clinical-grade and relevant cardiac data from the patient’s home, without any change in the user’s habits. With built in ECG, PPG, and BCG capabilities, it allows remote passive daily monitoring of heart rate, blood pressure, body weight, blood oxygen, impedence (fluid retation), pulmonary artery pressure, QRS duration, QTc interval, arrhythmias, and cardiac output / stroke volume, in one simple solution that patients don’t need to go out of their way to use, ensuring patient adherence. 

The Heart Seat has tested its cardiac measures in over 300 subjects in partnership with University of Rochester Medical Center. The Heart Seat has the potential to improve the quality of life for patients by allowing them to track health changes in the comfort of their own homes without the need to change their behavior.

Mercato is a SaaS platform for independent and specialty grocers, merchants, and artisans to offer the same level of local customer service and delivery that large chain supermarkets offer. Locally owned and operated markets are often superior to conglomerates and national chain brands: with an emphasis on quality foods, customized product offerings that serve the needs and preferences of their specific customer base rather than a one-size-fits-all approach, and superior service offered by owners that are stakeholders in the local community, customers prefer shopping locally when possible. Local stores, however, are at a severe disadvantage when it comes to technology, data, and buying power. Customers want an omni-channel shopping experience with selection and delivery that requires the resources of a corporate infrastructure. Mercato bridges the resource gap between local grocers and their chain competitors, offering e-commerce services such as product catalog creation, POS integration, online ordering, customized marketing, delivery (through partnership with popular third-party delivery services), pricing assistance, inventory tracking, and customer service. 

Providing healthy, safe, and trusted seafood products that support sustainability and diversity of our oceans. BlueNalu has overcome technical and business hurdles to become a pioneer in “cellular aquaculture” – a platform technology in which living cells isolated from fish tissue are placed into culture media for cellular proliferation – growing great-tasting fresh and frozen seafood products it can market as alternative proteins. BlueNalu’s seafood products are designed to be as nutritious as conventional seafood, produced in a way that is healthier for people, promotes humane treatment of animals, and ensures sustainability and ecological protection.

BlueNalu is especially focused on species that are over-fished, heavily imported, or difficult to farm – allowing a reduction in fisheries and foreign imports while creating local jobs and enhancing food security. BlueNalu is also able to avoid the use of genetic modification, antibiotics, or fetal bovine serum in their aquaculture – while remaining free of mercury and other environmental contaminants.

Eyedaptic has developed an AR (augmented reality) vision assistance device for Age-related Macular Degeneration (AMD) patients. Most vision assistance products on the market today only offer magnification, leaving the limited field of view unaddressed. 

Eyedaptic uses simulated natural vision software in their EYE2 to optimize peripheral vision, enabling viewing of the entire field of view (FOV) through reprojection of the content of the center of a user’s natural FOV into their peripheral vision. EYE2 is a non-invasive visual assistive AR-based smart eyewear device in the form-factor of a pair of glasses, customizable and adaptive to a user’s vision automatically through their proprietary software.

EYE2 allows users to regain freedom, move about easily without restrictions as a hands-free, easy-to-wear design, providing an improved quality of life.

Visgenx is developing a therapeutic for Age-Related Macular Degeneration (ARMD), the leading cause of irreversible blindness, which has no approved treatment. ARMD affects more than 11 million in the US and 196 million worldwide. Visgenx targets a severe form of macular degeneration known as “Geographic Atrophy” (GA).

Current therapies do not address ARMD or “dry” AMD, and only address the smaller subset of macular degeneration known as “wet AMD”. Visgenx’s science is licensed from research conducted at the Shiley Eye Institute at UCSD, identifying the age-related dysfunction of the ELOVL2 gene. Their therapeutic drug injection reverses gene dysfunction through demethylation, which has improved scotopic response in functional knock-out mice test subjects.

Aligned Carbon manufactures wafer-scale arrays of aligned carbon nanotubes (CNTs) to the exacting standards of integrated circuit foundries. 

Aligned Carbon can purify the CNT populations they synthesize to be entirely semiconducting or entirely metallic, opening a range of applications by addressing a key problem in a $500B market. These applications include CNT-Si hybrid monolithically integrated (stacked 3D) processors, which will be 1000x faster and more efficient than current single-layer processors, and RF data transmission circuitry, which can enable performance beyond 5G. 

Aligned Carbon delivers a unique foundry ready CNT material, and will grow the company through material sales as well as peripheral equipment and process capabilities to meet the market’s demands. Their 3D integrated circuit processors will be particularly disruptive to AI and other intensive computing fields.

Deep Blue Medical Advances is a surgical innovations company developing a novel hernia mesh to address the high rate of hernia occurrence and recurrence. Millions of hernia surgeries are done globally with billions of dollars in clinical cost; Deep Blue’s T-Line Hernia Mesh, with integral suture-like extensions, is designed to eliminate a key point of failure for conventional mesh fixation – the mesh/suture/tissue interface – and to provide superior anchor strength (up to 2.75x), advanced mesh tension adjustment, and the ability to use less mesh. 

In addition, their Anchor Clip fixation device design enables faster, stronger, easier mesh implantation. Deep Blue products enhance hernia surgery with a potentially significant impact on the $1.1B global hernia device market. T-Line Hernia Mesh has the potential to reduce hernia occurrence and recurrence by preventing or reducing mesh fixation failure.

Blackdot is building the first automatic tattoo machine. Aiming to revolutionize the tattoo experience for consumers, artists, and stores, Blackdot has several innovations in development, including an online tattoo marketplace where consumers can purchase designs from top artists around the world (including limited edition, unique one-off designs, and celebrity tattoos), temporary and less painful tattoos, quick sessions and perfectly replicable designs. 

Artist income would no longer tied to the number of hours they can physically tattoo in a specific location; shops would be able to increase customers per day and potentially expand to a franchise model. Brands could utilize temporary tattoos for advertisements and viral exposure. Customers would have massively increased selection and quality from top artists – on demand, less painfully with temporary options. Machines could be placed in mainstream stores – safer locations, more visibility, luxury tattoo experiences.

Insight Medical Systems is developing ARVIS (Augmented Reality Visualization and Information System). ARVIS combines tracking cameras with a 3D display and handsfree interface in a standalone surgical headset. The system, which includes a single tray of trackable instruments, provides the surgeon with key alignment and positioning data without the need for preoperative imaging or external equipment. ARVIS is worn and controlled by the surgeon, tracks from the surgeon’s viewpoint, and delivers information to the surgeon right at the point of care. 

The current standard is for surgeons to use guides or other external devices to assist in performing procedures, leading to inconsistent results and risking worse outcomes, longer operative times, litigation, and the need for expensive revision surgery. Current surgical robots and navigation systems increase accuracy and reproducibility of hip and knee replacement procedures but add cost, complexity and operative time. ARVIS has comparably accuracy but is faster and less expensive than robotic systems.

Noria Water Technologies specializes in Reverse Osmosis (RO) membrane optimization through their RO-Spotlight system. 

Fouling and mineral scaling place limits on the service lifetimes of membranes. As membranes may be used in sensitive, mission-critical, or health-related environments, companies must err on the side of caution and are often conservatively discarding viable membranes years before they need to be replaced. Noria can cut operating costs by 30% by simply allowing more efficient use of membrane technology, allowing facilities to scale back chemical usage, cleaning procedures with detrimental higher system pressure, allowing for easier stress testing and early failure detection, and reducing energy usage and overall downtime.

Used in advanced water treatment facilities such as wastewater recycling, desalination, and agricultural/food/beverage processing, it also has massive potential for industrial usage in mining, semiconductors, petrochemical and pharmaceutical applications.


Strategikon Pharma’s Clinical Maestro is a software platform designed for clinical study planning, seving to increase the efficiency and accuracy of planning, sourcing, modeling, contract and financial management. 

Pharma struggles with labor intensive manual processes leading to heavy staff infrastructures, workflow siloes and inefficiencies across the entire spectrum of clinical development. It usually takes multiple people to manage the non-operational aspects of clinical trial conduct and requires highly specialized expertise across finance and clinical ops.

Maestro is composed of two mirrored platforms, one targeting Pharma/Biotech companies (“Pharma Edition) and the clinical study service providers to whom biopharma companies outsource clinical development (“Provider Edition”). The two platforms consist of multiple modular applications (e.g. “planning”, “budgeting”, “RFP creation”, etc.) which can be deployed individually, or seamlessly interconnected to enable highly efficient management of the clinical business.

Labviva’s AI-based technology platform serves the buyers and suppliers in the 60B Life Science market by providing flexible tools with the ability to serve enriched scientific product catalog content from multiple suppliers in meaningful taxonomies that is valuable to researchers and purchasing professionals. 

Labviva seamlessly integrates with its client’s eProcurement platforms and enables purchasing departments to take control of their supply chain. Through greater visibility of purchasing trends, deep and insightful analytics and highly efficient onboarding of the tail spend, Labviva is providing its clients with significant cost savings. Two target markets are procurement professionals (focusing on ease of integration with buyer’s purchasing platforms, ease of on-boarding of the tail spend suppliers and comprehensive purchasing analytics) and scientific staff (comprehensive product data, contextual representation of products in research applications, and availability of supporting scientific literature to inform their decision making process.

Gali is working to create personalized medical solutions for sufferers of chronic conditions through a pioneering combination of app-based patient surveying and population-scale analysis of genomic, lifestyle, and health backgrounds.

Currently focusing on inflammatory bowel diseases (IBD) such as Crohn’s and Colitis, Gali aims to provide users with AI-assisted personalized disease self-management through their app, providing support for medical, psychological, and lifestyle issues through a combination of analysis of self-reported and collective user trends, the latest information from healthcare professionals and researchers, and genomic data provided by users and other databases. With tens of thousands of users, Gali will have the largest sample-size of IBD sufferers in history, and will be able to leverage massive synergetic data sets with common lifestyle, diet, genetic and historical health backgrounds to recommend effective treatments and management techniques for users with similar data points, as well as being able to contribute to medical and pharmaceutical research.

Maxwell Biomedical is in the 5th generation of development of a wireless, batteryless micro-pacing system implanted device approach to pace atrial fibrillation patients back to normal sinus rhythm. 

Atrial fibrillation is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications. Current treatments are either ineffective toxic drugs, or ablation procedures (with a 50% failure rate after 1 year). A micro-pacing system is more effective, but none have been able to work painlessly before now. 

Maxwell’s micro-pacing system is made up of a micro-flexible PCB and an antenna on a stent-like anchor delivered into the Vein of Marshal (VoM). A handheld device serves as the wireless power supply and performs patient monitoring and AF detection. Maxwell will target persistent (24/7) Afib patients as well as those with failed ablation procedures.

Upcycle & Co’s Native Soil is is a sustainable natural fertilizer made of local, naturally sourced organic matter. Carbon, an essential component of healthy soil, is rarely included in commercially available fertilizers. Carbon is rapidly oxidized in arid climates such as the Southwestern United States and must be routinely replenished to maintain adequate levels for soil health. Organic Matter affects the chemical and physical properties of soil and its overall health. Its composition and breakdown rate affect soil structure, porosity, moisture holding capacity, biological diversity, and nutrient availability. Native Soil incorporates the macronutrients contained in commercial fertilizers into a biologically derived carbon matrix and adds naturally occurring organic matter, saving money by reducing the number of fertilizer applications every year, building soil structure, reducing water usage, labor and O&M costs, and minimizing runoff and water pollution.

1st generation autologous chimeric antigen receptor T cells (“CAR-T”) and 2nd generation allogeneic CAR-T are ex vivo procedures that modify cells outside their native environment, have high COGS and face challenges with scalability and patient access. In contrast, Abintus is advancing 3rd generation in vivo CAR-T products that may be administered directly to patients. This approach can have the potential to address many of the current scientific and commercial challenges faced by companies with ex vivo CAR-T product and technology platforms. Based on highly customizable retroviral non-replicating vectors. Abintus is developing its lead investigational product candidate, RNV-CD19CAR, for the treatment of blood cancers such as lymphoma. Having products that may ultimately be available in an out-patient setting will provide greater patient access to potentially life saving treatments and provide a solution so that hospitals no longer lose money via inadequate NTAP reimbursement.


Our Investment Profile

  • We typically fund $300K to $1M for financing rounds that we lead
  • Our deals are led by an Annual Fund (see Fund FAQ here), and supplemented by individual member checks at the option of our entrepreneurs
  • We typically focus on technology and life science, although we will consider other high-growth companies that serve large addressable markets
  • Deals we lead are typically located in San Diego and surrounding region
  • We can also “top off” deals brought by other trusted groups (angel networks, micro VCs, and family offices) through a fast and efficient syndication process

Our Process

  • Initial screening
  • Presentation at monthly membership meeting
  • Due Diligence period (80% completed in first meeting, 29 days for remaining items)
  • Optional: Gain additional visibility (and funding) through TCA dinner meetings and partner syndication presentations
  • Funding!



Nii A. Ahene

Nii A. Ahene

Sonia Steinway

Sonia Steinway

Outside Financial
Joyce Tang

Joyce Tang



Nicole Pereira

Nicole Pereira

Ilana Brand

Ilana Brand

Michael Umansky

Michael Umansky

Sheppard Mullin


Alex Lee

Alex Lee

Acai Inc.
Ruichen Sun

Ruichen Sun

UCSD - Neuroscientist
Alexander Polus

Alexander Polus

UCSD, Artificial Intelligence and Entrepreneurship

Have a question/comment for us?

4 + 3 = ?


Loading RSS Feed

Let’s Get Connected!